357669-69-3

Basic information

• Product Name: (4R,5R)-5-[N-benzyl-N-(2-oxo-2-phenylethyl)carbamoyl]-2,2-dimethyl[1,3]dioxolane-4-carboxylic acid methyl ester
• Synonyms: (4R,5R)-5-[N-benzyl-N-(2-oxo-2-phenylethyl)carbamoyl]-2,2-dimethyl[1,3]dioxolane-4-carboxylic acid methyl ester
• CAS NO: 357669-69-3
• Molecular Weight: 411.455
• Mol File: 357669-69-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (4R,5R)-5-[N-benzyl-N-(2-oxo-2-phenylethyl)carbamoyl]-2,2-dimethyl[1,3]dioxolane-4-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (4R,5R)-5-[N-benzyl-N-(2-oxo-2-phenylethyl)carbamoyl]-2,2-dimethyl[1,3]dioxolane-4-carboxylic acid methyl ester(357669-69-3)
• EPA Substance Registry System: (4R,5R)-5-[N-benzyl-N-(2-oxo-2-phenylethyl)carbamoyl]-2,2-dimethyl[1,3]dioxolane-4-carboxylic acid methyl ester(357669-69-3)

Safety Data

• Hazardous Substances Data: 357669-69-3(Hazardous Substances Data)

Upstream product

• 67812-33-3 (4R,5R)-5-(methoxycarbonyl)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid 
• 31410-16-9 2-benzylamino-1-phenyl-1-ethanone hydrobromide 
• 50606-93-4 α-(N-Benzylamino)acetophenone 
• 67844-12-6 methyl (4S,5S)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid-5-carboxylate 
• 100-46-9 benzylamine 
• 70-11-1 α-bromoacetophenone 

Downstream Products

• 357669-64-8 (1R,5S,7R)-3-benzyl-2-oxo-5-phenyl-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid methyl ester 

Relevant articles and documents

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO NEUROTROPHINES

The present invention refers to pharmaceutical preparations including as active compounds 3-aza-bicyclo[3.2.1]octane derivatives of general formula (I) and/or their dimers of general formula (II) and (III) acting as agonists of human neurotrophines. Therefore, such compounds of formula (I), (II) and (III) are useful for treatment of diseases in which the neurotrophine functions are involved in defect, particularly of Nerve Growth Factor (NGF), such as neurodegenerative diseases of central nervous system (CNS), acquired immundeficiency due to a reduced NGF biodisponibility, or morbous conditions in which the stimulus of neoangiogenesis process is convenient.